AnaptysBio, Inc (ANAB) stock analysis
Close on Oct 19, 2026Market cap $1.73BP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
AnaptysBio passes 9 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 2/6
- Past performance
- 2/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
AnaptysBio has no borrowings on its latest balance sheet.
Revenue growing 10%+ a year
Revenue grew 184% a year over the last three fiscal years.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
What to watch
No dividend
AnaptysBio has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth2/6
Revenue growing 10%+ a year
Revenue grew 184% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 92.9% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was 82.4% over the last twelve months, against a 5-year average of -492%.
Net margin above the industry
AnaptysBio's net margin of 82.4% is above the Drugs median of -53.0%.
Financial health5/6
No debt
AnaptysBio has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 5.61 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
AnaptysBio has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for AnaptysBio. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- EV/EBITDA at month end
- Drugs median 17.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Margins
Share of revenue, fiscal years 2014 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +157.0% | +183.6% | +25.6% | +29.6% | |
| Operating income | +243.0% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.6% | -5.0% | -24.5% | |
| Return on assets | – | -4.7% | -3.1% | |
| Current ratio | 10.20 | 20.01 | 9.07 | |
| Interest coverage | -6.6× | – | – | |
| Capex to revenue | 0.3% | 0.8% | 0.0% | |
| Diluted shares | 3M | 27M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
AnaptysBio generated $395.35M from operations and spent $122.06M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -5.6% | 0.55× | 7.85× | -24.5% |
| FY2024 | -159.1% | 0.19× | 5.89× | -182.7% |
| FY2023 | -953.7% | 0.03× | 3.03× | -93.4% |
| FY2022 | -1251.3% | 0.02× | 2.03× | -41.6% |
| FY2021 | -91.5% | 0.12× | 1.41× | -15.3% |
| FY2020 | -26.6% | 0.18× | 1.06× | -5.0% |
| FY2019 | -1216.7% | 0.02× | 1.06× | -21.8% |
| FY2018 | -1233.1% | 0.01× | 1.06× | -15.5% |
| FY2017 | -300.7% | 0.05× | 1.45× | -22.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$13.23M
- Cash generatingOperating cash flow above zero$19.70M
- Return on assets improvedROA up on the prior year-32.1% → -2.7%
- Earnings backed by cashOperating cash flow above net income$19.70M vs -$13.23M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.51 → 9.07
- No dilutionShare count did not rise30M → 30M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.20 → 0.48
See a number that looks wrong?